{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:57Z","timestamp":1789712817412,"version":"4.0.1"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T00:00:00Z","timestamp":1473033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["AI424-552"],"award-info":[{"award-number":["AI424-552"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA MERIT","award":["I01 CX000418-01A1"],"award-info":[{"award-number":["I01 CX000418-01A1"]}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["#50782"],"award-info":[{"award-number":["#50782"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI068636"],"award-info":[{"award-number":["U01AI068636"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11904-016-0333-9","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T04:53:50Z","timestamp":1473051230000},"page":"328-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Metabolic and Cardiovascular Complications in HIV\/HCV-Co-infected Patients"],"prefix":"10.1007","volume":"13","author":[{"given":"Roger","family":"Bedimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladapo","family":"Abodunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"key":"333_CR1","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"TT Brown","year":"2006","unstructured":"Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165\u201374.","journal-title":"AIDS"},{"key":"333_CR2","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/jbmr.1988","volume":"28","author":"NM Maalouf","year":"2013","unstructured":"Maalouf NM, Zhang S, Drechsler H, Brown GR, Tebas P, Bedimo R. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res. 2013;28:2577\u201383.","journal-title":"J Bone Miner Res"},{"key":"333_CR3","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","volume":"93","author":"VA Triant","year":"2008","unstructured":"Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499\u2013504.","journal-title":"J Clin Endocrinol Metab"},{"key":"333_CR4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","volume":"51","author":"GA McComsey","year":"2010","unstructured":"McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937\u201346.","journal-title":"Clin Infect Dis"},{"key":"333_CR5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.25866","volume":"56","author":"V Lo Re 3rd","year":"2012","unstructured":"Lo Re 3rd V, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection. Hepatology. 2012;56:1688\u201398.","journal-title":"Hepatology"},{"key":"333_CR6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","volume":"26","author":"R Bedimo","year":"2012","unstructured":"Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825\u201331.","journal-title":"AIDS"},{"key":"333_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAD.0b013e32834ed8a7","volume":"26","author":"AB Hansen","year":"2012","unstructured":"Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285\u201393.","journal-title":"AIDS"},{"key":"333_CR8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1086\/520144","volume":"29","author":"CT Staples Jr","year":"1999","unstructured":"Staples Jr CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150\u20134.","journal-title":"Clin Infect Dis"},{"key":"333_CR9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/QAI.0b013e3181831e85","volume":"49","author":"SS Solomon","year":"2008","unstructured":"Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, et al. High prevalence of HIV, HIV\/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008;49:327\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR10","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","volume":"42","author":"P Cacoub","year":"1999","unstructured":"Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204\u201312.","journal-title":"Arthritis Rheum"},{"key":"333_CR11","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","volume":"20","author":"LE Adinolfi","year":"2014","unstructured":"Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410\u20137.","journal-title":"World J Gastroenterol"},{"key":"333_CR12","doi-asserted-by":"crossref","unstructured":"Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016.","DOI":"10.1111\/liv.13064"},{"key":"333_CR13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","volume":"149","author":"F Negro","year":"2015","unstructured":"Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345\u201360.","journal-title":"Gastroenterology"},{"key":"333_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000719","volume":"6","author":"DL Diamond","year":"2010","unstructured":"Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, Proll SC, et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog. 2010;6, e1000719.","journal-title":"PLoS Pathog"},{"key":"333_CR15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","volume":"160","author":"V Lo Re 3rd","year":"2014","unstructured":"Lo Re 3rd V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369\u201379.","journal-title":"Ann Intern Med"},{"key":"333_CR16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/644771","volume":"49","author":"TY Chen","year":"2009","unstructured":"Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605\u201315.","journal-title":"Clin Infect Dis"},{"key":"333_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jvh.12447","volume":"23","author":"JV Fernandez-Montero","year":"2016","unstructured":"Fernandez-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47\u201352.","journal-title":"J Viral Hepat"},{"key":"333_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00126334-200107010-00005","volume":"27","author":"M Duong","year":"2001","unstructured":"Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245\u201350.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR19","unstructured":"Weber R, Sabin CA, Reiss P, De Wit S, Worm S, Law MG, et al. Hepatitis virus co-infections and risk of diabetes mellitus and myocardial infarction in HIV-infected persons: the D:A:D study. In: 15th Conference on Retroviruses and Opportunistic Infections. Edited by. Boston, Massachusetts; 2008, February."},{"key":"333_CR20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0b013e3283574e71","volume":"26","author":"L Peters","year":"2012","unstructured":"Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917\u201326.","journal-title":"AIDS"},{"key":"333_CR21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/QAD.0b013e32833ce54d","volume":"24","author":"IF Castro de","year":"2010","unstructured":"de Castro IF, Micheloud D, Berenguer J, Guzman-Fulgencio M, Catalan P, Miralles P, et al. Hepatitis C virus infection is associated with endothelial dysfunction in HIV\/hepatitis C virus coinfected patients. AIDS. 2010;24:2059\u201367.","journal-title":"AIDS"},{"key":"333_CR22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10096-006-0090-6","volume":"25","author":"GF Larranaga de","year":"2006","unstructured":"de Larranaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis. 2006;25:98\u2013103.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"333_CR23","doi-asserted-by":"crossref","unstructured":"Peters L, Neuhaus J, Duprez D, Neaton JD, Tracy R, Klein MB, et al. Biomarkers of inflammation, coagulation and microbial translocation in HIV\/HCV co-infected patients in the SMART study. J Clin Virol. 2014;60:295\u2013300. This study showed that HIV\/HCV-co-infected persons with impaired liver function display an enhanced pro-inflammatory state, further exacerbated upon interruption of ART.","DOI":"10.1016\/j.jcv.2014.03.017"},{"key":"333_CR24","doi-asserted-by":"crossref","unstructured":"Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293\u2013302. In this large Taiwanese cohort, treatment for HCV infection is associated with improved renal and cardiovascular outcomes in diabetic patients.","DOI":"10.1002\/hep.26892"},{"key":"333_CR25","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","volume":"76","author":"P Andre","year":"2002","unstructured":"Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002;76:6919\u201328.","journal-title":"J Virol"},{"key":"333_CR26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0033-1358524","volume":"33","author":"EA Schaefer","year":"2013","unstructured":"Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis. 2013;33:358\u201368.","journal-title":"Semin Liver Dis"},{"key":"333_CR27","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.25990","volume":"57","author":"JE Lambert","year":"2013","unstructured":"Lambert JE, Bain VG, Ryan EA, Thomson AB, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology. 2013;57:1697\u2013704.","journal-title":"Hepatology"},{"key":"333_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","volume":"49","author":"CY Dai","year":"2008","unstructured":"Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49:9\u201316.","journal-title":"J Hepatol"},{"key":"333_CR29","doi-asserted-by":"crossref","unstructured":"Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB, team Es. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis. 2015;15:510. This longitudinal study demonstrates progressive declines of lipoprotein levels after HCV acquisition.","DOI":"10.1186\/s12879-015-1268-2"},{"key":"333_CR30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-1293.2006.00416.x","volume":"7","author":"R Bedimo","year":"2006","unstructured":"Bedimo R, Ghurani R, Nsuami M, Turner D, Kvanli MB, Brown G, et al. Lipid abnormalities in HIV\/hepatitis C virus-coinfected patients. HIV Med. 2006;7:530\u20136.","journal-title":"HIV Med"},{"key":"333_CR31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/00002030-200304110-00023","volume":"17","author":"J Collazos","year":"2003","unstructured":"Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS. 2003;17:927\u20139.","journal-title":"AIDS"},{"key":"333_CR32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00126334-200405010-00015","volume":"36","author":"S Giambenedetto Di","year":"2004","unstructured":"Di Giambenedetto S, Baldini F, Cingolani A, Tamburrini E, Cauda R, De Luca A. The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;36:641\u20132.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1310\/W024-QC4T-NXU0-TKYT","volume":"3","author":"A Patroni","year":"2002","unstructured":"Patroni A, Torti C, Tomasoni L, Roldan EQ, Bertelli D, Puoti M, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002;3:451\u201361.","journal-title":"HIV Clin Trials"},{"key":"333_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1468-1293.2005.00269.x","volume":"6","author":"A Richter","year":"2005","unstructured":"Richter A, Pladevall M, Manjunath R, Lafata JE, Xi H, Simpkins J, et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 2005;6:79\u201390.","journal-title":"HIV Med"},{"key":"333_CR35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00126334-200303010-00018","volume":"32","author":"A Rodriguez-Guardado","year":"2003","unstructured":"Rodriguez-Guardado A, Maradona JA, Asensi V, Carton JA, Casado L. Hepatitis C virus in patients with HIV infection and lipodystrophy. J Acquir Immune Defic Syndr. 2003;32:348\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/jac\/dki063","volume":"55","author":"ML Montes","year":"2005","unstructured":"Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir\/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55:800\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"333_CR37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1468-1293.2004.00202.x","volume":"5","author":"PM Polgreen","year":"2004","unstructured":"Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med. 2004;5:144\u201350.","journal-title":"HIV Med"},{"key":"333_CR38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/apc.2006.0150","volume":"21","author":"M Floris-Moore","year":"2007","unstructured":"Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDs. 2007;21:479\u201391.","journal-title":"AIDS Patient Care STDs"},{"key":"333_CR39","doi-asserted-by":"crossref","unstructured":"Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61:790\u2013801. This study analyzes the changes in peripheral and intra-hepatic lipid metabolism in response to antiviral therapy with direct-acting antiviral drugs.","DOI":"10.1002\/hep.27424"},{"key":"333_CR40","doi-asserted-by":"crossref","unstructured":"Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, et al. Interferon-free treatment of hepatitis C virus in HIV\/hepatitis C virus-coinfected subjects results in increased serum low-density lipoprotein concentration. AIDS Res Hum Retrovir. 2016;32:456\u201362. This study showed increases in low-density lipoproteins among HIV\/HCV-co-infected patients during treatment with direct-acting antiviral drugs, and suggests that those changes lag behind reductions in HCV viremia.","DOI":"10.1089\/aid.2015.0170"},{"key":"333_CR41","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.23219","volume":"50","author":"KE Corey","year":"2009","unstructured":"Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009;50:1030\u20137.","journal-title":"Hepatology"},{"key":"333_CR42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1096\/fj.01-0396com","volume":"16","author":"G Perlemuter","year":"2002","unstructured":"Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:185\u201394.","journal-title":"FASEB J"},{"key":"333_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/B:DDAS.0000011597.92851.56","volume":"49","author":"P Sharma","year":"2004","unstructured":"Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci. 2004;49:25\u20139.","journal-title":"Dig Dis Sci"},{"key":"333_CR44","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","volume":"33","author":"LE Adinolfi","year":"2001","unstructured":"Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358\u201364.","journal-title":"Hepatology"},{"key":"333_CR45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/cid\/civ101","volume":"60","author":"CG Morse","year":"2015","unstructured":"Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60:1569\u201378.","journal-title":"Clin Infect Dis"},{"key":"333_CR46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1665-2681(19)31315-8","volume":"12","author":"V Li Vecchi","year":"2013","unstructured":"Li Vecchi V, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, La Spada E, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV\/HCV- and HCV-infected patients. Ann Hepatol. 2013;12:740\u20138.","journal-title":"Ann Hepatol"},{"key":"333_CR47","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.ijid.2012.01.011","volume":"16","author":"V Li Vecchi","year":"2012","unstructured":"Li Vecchi V, Soresi M, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis. 2012;16:e397\u2013402.","journal-title":"Int J Infect Dis"},{"key":"333_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S Grinspoon","year":"2005","unstructured":"Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48\u201362.","journal-title":"N Engl J Med"},{"key":"333_CR49","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592\u20138.","journal-title":"Lancet"},{"key":"333_CR50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","volume":"62","author":"GA McComsey","year":"2016","unstructured":"McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dube MP, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62:853\u201362.","journal-title":"Clin Infect Dis"},{"key":"333_CR51","volume":"2","author":"JE Lake","year":"2015","unstructured":"Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, et al. Switch to raltegravir from protease inhibitor or nonnucleoside reverse-transcriptase inhibitor does not reduce visceral fat in human immunodeficiency virus-infected women with central adiposity. Open Forum Infect Dis. 2015;2, ofv059.","journal-title":"Open Forum Infect Dis"},{"key":"333_CR52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.23859","volume":"52","author":"S Petta","year":"2010","unstructured":"Petta S, Amato M, Cabibi D, Camma C, Di Marco V, Giordano C, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010;52:1543\u201352.","journal-title":"Hepatology"},{"key":"333_CR53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gut.2009.202317","volume":"59","author":"A Mostafa","year":"2010","unstructured":"Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010;59:1135\u201340.","journal-title":"Gut"},{"key":"333_CR54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/QAI.0b013e3180423a95","volume":"45","author":"PC Tien","year":"2007","unstructured":"Tien PC, Bacchetti P, Gripshover B, Overton ET, Rimland D, Kotler D, et al. Metabolic change in HIVISI: association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women. J Acquir Immune Defic Syndr. 2007;45:60\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.7326\/M14-2525","volume":"163","author":"KR Sahakyan","year":"2015","unstructured":"Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163:827\u201335.","journal-title":"Ann Intern Med"},{"key":"333_CR56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/09540121.2010.543885","volume":"23","author":"JE Lake","year":"2011","unstructured":"Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care. 2011;23:929\u201338.","journal-title":"AIDS Care"},{"key":"333_CR57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","volume":"134","author":"R Moucari","year":"2008","unstructured":"Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416\u201323.","journal-title":"Gastroenterology"},{"key":"333_CR58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1365-2036.2009.04094.x","volume":"30","author":"E Tsochatzis","year":"2009","unstructured":"Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, et al. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther. 2009;30:947\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"333_CR59","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.25867","volume":"56","author":"A Aghemo","year":"2012","unstructured":"Aghemo A, Prati GM, Rumi MG, Soffredini R, D\u2019Ambrosio R, Orsi E, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56:1681\u20137.","journal-title":"Hepatology"},{"key":"333_CR60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apt.12234","volume":"37","author":"ZM Younossi","year":"2013","unstructured":"Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"333_CR61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.510290235","volume":"29","author":"AL Mason","year":"1999","unstructured":"Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328\u201333.","journal-title":"Hepatology"},{"key":"333_CR62","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1365-2036.2006.03114.x","volume":"24","author":"E Durante-Mangoni","year":"2006","unstructured":"Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin\/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349\u201357.","journal-title":"Aliment Pharmacol Ther"},{"key":"333_CR63","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.22269","volume":"47","author":"MY Sheikh","year":"2008","unstructured":"Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008;47:2127\u201333.","journal-title":"Hepatology"},{"key":"333_CR64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","volume":"23","author":"AA Butt","year":"2009","unstructured":"Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227\u201334.","journal-title":"AIDS"},{"key":"333_CR65","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/dme.12455","volume":"31","author":"A Tripathi","year":"2014","unstructured":"Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31:1185\u201393.","journal-title":"Diabet Med"},{"key":"333_CR66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/518619","volume":"45","author":"B Ledergerber","year":"2007","unstructured":"Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111\u20139.","journal-title":"Clin Infect Dis"},{"key":"333_CR67","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1097\/QAD.0b013e32827038ad","volume":"21","author":"GM Lucas","year":"2007","unstructured":"Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007;21:2435\u201343.","journal-title":"AIDS"},{"key":"333_CR68","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/QAD.0b013e328357f5ed","volume":"26","author":"RC Kalayjian","year":"2012","unstructured":"Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26:1907\u201315.","journal-title":"AIDS"},{"key":"333_CR69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/QAI.0b013e3181b980d4","volume":"53","author":"MJ Fischer","year":"2010","unstructured":"Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, Rimland D, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr. 2010;53:222\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR70","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw050","volume":"3","author":"CT Costiniuk","year":"2016","unstructured":"Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, et al. Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. Open Forum Infect Dis. 2016;3, ofw050.","journal-title":"Open Forum Infect Dis"},{"key":"333_CR71","unstructured":"Mehsen N, Lawson-Ayayi S, Schaeverbeke T, Pellegrin I, Mercie P, Barthe N, et al. Cardiovascular risk and osteoporosis are associated in HIV-infected patients, ANRS CO3 Aquitaine Cohort, France. In: 6th International AIDS Society Conference. Edited by. Rome, Italy; 2011:Abstract TUPE246."},{"key":"333_CR72","doi-asserted-by":"crossref","unstructured":"Lai H, Moore R, Celentano DD, Gerstenblith G, Treisman G, Keruly JC, et al. HIV infection itself may not be associated with subclinical coronary artery disease among African Americans without cardiovascular symptoms. J Am Heart Assoc. 2016;4:e002529. This study suggests that it is antiretroviral therapy, but not HIV infection itself, that is associated with increased risk of subclinical atherosclerosis in HIV patients.","DOI":"10.1161\/JAHA.115.002529"},{"key":"333_CR73","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-1293.2009.00815.x","volume":"11","author":"R Bedimo","year":"2010","unstructured":"Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462\u20138.","journal-title":"HIV Med"},{"key":"333_CR74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/cis933","volume":"56","author":"M Helleberg","year":"2013","unstructured":"Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727\u201334.","journal-title":"Clin Infect Dis"},{"key":"333_CR75","doi-asserted-by":"crossref","unstructured":"Rasmussen LD, Helleberg M, May M, Afzal S, Kronborg G, Larsen CS, et al. Myocardial infarction among Danish HIV-infected individuals: population attributable fractions associated with smoking. Clin Infect Dis. 2015. This study highlights the importance of smoking in the cardiovascular risk of HIV-infected patients.","DOI":"10.1093\/cid\/civ013"},{"key":"333_CR76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.ATV.0000251503.35795.4f","volume":"27","author":"W Koenig","year":"2007","unstructured":"Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"333_CR77","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0000000000000138","volume":"66","author":"A Tawakol","year":"2014","unstructured":"Tawakol A, Lo J, Zanni MV, Marmarelis E, Ihenachor EJ, MacNabb M, et al. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr. 2014;66:164\u201371.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR78","doi-asserted-by":"crossref","unstructured":"El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, et al. Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART. J Lipid Res. 2015.","DOI":"10.1194\/jlr.M054510"},{"key":"333_CR79","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383\u201393.","journal-title":"N Engl J Med"},{"key":"333_CR80","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/QAI.0000000000000900","volume":"71","author":"KA Rose","year":"2016","unstructured":"Rose KA, Vera JH, Drivas P, Banya W, Keenan N, Pennell DJ, et al. Atherosclerosis is evident in treated HIV-infected subjects with low cardiovascular risk by carotid cardiovascular magnetic resonance. J Acquir Immune Defic Syndr. 2016;71:514\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR81","doi-asserted-by":"crossref","unstructured":"Monroe AK, Haberlen SA, Post WS, Palella FJ, Jr., Kinsgley LA, Witt MD, et al. Cardiovascular disease risk scores\u2019 relationship to subclinical cardiovascular disease among HIV-infected and-uninfected men. AIDS. 2016.","DOI":"10.1097\/QAD.0000000000001163"},{"key":"333_CR82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","volume":"58","author":"S Maruyama","year":"2013","unstructured":"Maruyama S, Koda M, Oyake N, Sato H, Fujii Y, Horie Y, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2013;58:11\u20135.","journal-title":"J Hepatol"},{"key":"333_CR83","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.25508","volume":"55","author":"S Petta","year":"2012","unstructured":"Petta S, Torres D, Fazio G, Camma C, Cabibi D, Di Marco V, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology. 2012;55:1317\u201323.","journal-title":"Hepatology"},{"key":"333_CR84","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2012.02.027","volume":"222","author":"P Sosner","year":"2012","unstructured":"Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis. 2012;222:274\u20137.","journal-title":"Atherosclerosis"},{"key":"333_CR85","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2334-11-265","volume":"11","author":"M Masia","year":"2011","unstructured":"Masia M, Padilla S, Robledano C, Ramos JM, Gutierrez F. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infect Dis. 2011;11:265.","journal-title":"BMC Infect Dis"},{"key":"333_CR86","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","volume":"221","author":"LE Adinolfi","year":"2012","unstructured":"Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496\u2013502.","journal-title":"Atherosclerosis"},{"key":"333_CR87","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362\u201371.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"333_CR88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1468-1293.2008.00661.x","volume":"10","author":"US Kristoffersen","year":"2009","unstructured":"Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 2009;10:79\u201387.","journal-title":"HIV Med"},{"key":"333_CR89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/QAI.0b013e318189a794","volume":"49","author":"AC Ross","year":"2008","unstructured":"Ross AC, Armentrout R, O\u2019Riordan MA, Storer N, Rizk N, Harrill D, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr. 2008;49:499\u2013506.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5, e203.","journal-title":"PLoS Med"},{"key":"333_CR91","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780\u201390.","journal-title":"J Infect Dis"},{"key":"333_CR92","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"AR Tenorio","year":"2014","unstructured":"Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248\u201359.","journal-title":"J Infect Dis"},{"key":"333_CR93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","volume":"164","author":"CP Oliveira","year":"2013","unstructured":"Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2013;164:221\u20136.","journal-title":"Int J Cardiol"},{"key":"333_CR94","doi-asserted-by":"crossref","unstructured":"Shmagel KV, Saidakova EV, Shmagel NG, Korolevskaya LB, Chereshnev VA, Robinson J, et al. Systemic inflammation and liver damage in HIV\/hepatitis C virus coinfection. HIV Med. 2016.","DOI":"10.1111\/hiv.12357"},{"key":"333_CR95","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/QAI.0b013e3181685727","volume":"48","author":"J Reingold","year":"2008","unstructured":"Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, et al. Association of HIV infection and HIV\/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008;48:142\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/intimm\/dxh024","volume":"16","author":"L Kalabay","year":"2004","unstructured":"Kalabay L, Nemesanszky E, Csepregi A, Pusztay M, David K, Horvath G, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol. 2004;16:51\u20134.","journal-title":"Int Immunol"},{"key":"333_CR97","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","volume":"17","author":"N Friis-Moller","year":"2003","unstructured":"Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d\u2019Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179\u201393.","journal-title":"AIDS"},{"key":"333_CR98","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","volume":"165","author":"TT Brown","year":"2005","unstructured":"Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179\u201384.","journal-title":"Arch Intern Med"},{"key":"333_CR99","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","volume":"31","author":"S Wit De","year":"2008","unstructured":"De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224\u20139.","journal-title":"Diabetes Care"},{"key":"333_CR100","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","volume":"289","author":"SA Riddler","year":"2003","unstructured":"Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978\u201382.","journal-title":"JAMA"},{"key":"333_CR101","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/QAD.0b013e32835fd8a9","volume":"27","author":"CM Parrinello","year":"2013","unstructured":"Parrinello CM, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, et al. Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women\u2019s Interagency HIV study. AIDS. 2013;27:1516\u20139.","journal-title":"AIDS"},{"key":"333_CR102","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkt468","volume":"69","author":"S Orden","year":"2014","unstructured":"Orden S, De Pablo C, Rios-Navarro C, Martinez-Cuesta MA, Peris JE, Barrachina MD, et al. Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95. J Antimicrob Chemother. 2014;69:995\u20131004.","journal-title":"J Antimicrob Chemother"},{"key":"333_CR103","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI200316261","volume":"111","author":"J Dressman","year":"2003","unstructured":"Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389\u201397.","journal-title":"J Clin Invest"},{"key":"333_CR104","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/labinvest.2009.85","volume":"89","author":"X Wang","year":"2009","unstructured":"Wang X, Liao D, Lin PH, Yao Q, Chen C. Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. Lab Investig. 2009;89:1355\u201363.","journal-title":"Lab Investig"},{"key":"333_CR105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cardiores.2004.03.020","volume":"63","author":"BS Conklin","year":"2004","unstructured":"Conklin BS, Fu W, Lin PH, Lumsden AB, Yao Q, Chen C. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res. 2004;63:168\u201375.","journal-title":"Cardiovasc Res"},{"key":"333_CR106","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/QAD.0b013e32834d3cc3","volume":"25","author":"PD Baum","year":"2011","unstructured":"Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011;25:2243\u20138.","journal-title":"AIDS"},{"key":"333_CR107","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/QAD.0b013e32835abcc9","volume":"27","author":"S Piconi","year":"2013","unstructured":"Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 2013;27:381\u20139.","journal-title":"AIDS"},{"key":"333_CR108","doi-asserted-by":"crossref","unstructured":"Chew KW, Hua L, Bhattacharya D, Butt AA, Bornfleth L, Chung RT, et al. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus\/hepatitis C virus coinfection. Open Forum Infectious Diseases. 2014;1.","DOI":"10.1093\/ofid\/ofu104"},{"key":"333_CR109","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/jac\/dkr202","volume":"66","author":"M Masia","year":"2011","unstructured":"Masia M, Robledano C, Lopez N, Escolano C, Gutierrez F. Treatment for hepatitis C virus with pegylated interferon-alpha plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. J Antimicrob Chemother. 2011;66:1861\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"333_CR110","unstructured":"Klein D, Hurley L, Quesenberry C, Silverberg M, Horberg M, Sidney S. Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: changes in practice and Framingham risk scores. In 13th Conference on Retroviruses and Opportunistic Infections. Denver; 2006."},{"key":"333_CR111","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","volume":"30","author":"D Klein","year":"2002","unstructured":"Klein D, Hurley LB, Quesenberry Jr CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR112","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","volume":"118","author":"JS Currier","year":"2008","unstructured":"Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29\u201335.","journal-title":"Circulation"},{"key":"333_CR113","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","volume":"92","author":"VA Triant","year":"2007","unstructured":"Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"333_CR114","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1086\/518285","volume":"44","author":"N Obel","year":"2007","unstructured":"Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625\u201331.","journal-title":"Clin Infect Dis"},{"key":"333_CR115","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e31817efb54","volume":"48","author":"C Lewden","year":"2008","unstructured":"Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the \u201cMortalite 2000 and 2005\u201d surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR116","unstructured":"Hurley LB, Leyden W, Xu L, Silverberg M, Chao C, Tang B, et al. Updated surveillance of cardiovascular event rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008. In: 16th Conference on Retroviruses and Opportunistic Infections. Edited by; 2009:Abstract #710."},{"key":"333_CR117","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s10620-014-3222-3","volume":"59","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Kanwal F, Younossi ZM, Ahmed A. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci. 2014;59:1586\u201393.","journal-title":"Dig Dis Sci"},{"key":"333_CR118","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c85feb29-046d-45f6-ba12-510f9e1d9412","volume":"9","author":"H Huang","year":"2014","unstructured":"Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS One. 2014;9, e106376.","journal-title":"PLoS One"},{"key":"333_CR119","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1475-097X.2012.01152.x","volume":"32","author":"T Roed","year":"2012","unstructured":"Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging. 2012;32:421\u201330.","journal-title":"Clin Physiol Funct Imaging"},{"key":"333_CR120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cir269","volume":"53","author":"RJ Bedimo","year":"2011","unstructured":"Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53:84\u201391.","journal-title":"Clin Infect Dis"},{"key":"333_CR121","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3851\/IMP1681","volume":"15","author":"R Weber","year":"2010","unstructured":"Data Collection on Adverse Events of Anti HIVDSG, Weber R, Sabin C, Reiss P, de Wit S, Worm SW, et al. Antivir Ther. 2010;15:1077\u201386.","journal-title":"Antivir Ther"},{"key":"333_CR122","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3851\/IMP2724","volume":"19","author":"J Gillis","year":"2014","unstructured":"Gillis J, Smieja M, Cescon A, Rourke SB, Burchell AN, Cooper C, et al. Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther. 2014;19:309\u201317.","journal-title":"Antivir Ther"},{"key":"333_CR123","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","volume":"7","author":"MG Law","year":"2006","unstructured":"Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D\u2019Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218\u201330.","journal-title":"HIV Med"},{"key":"333_CR124","unstructured":"Drechsler H, Ayers C, Cutrell J, Maalouf NM, Tebas P, Bedimo R. The 2013 AHA\/ACC pooled cohort risk equations perform better than Framingham score but still underestimate CVD risk in HIV+ veterans. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy;. Edited by. Washington, D.C.; 2014."},{"key":"333_CR125","doi-asserted-by":"crossref","unstructured":"Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, et al. Short communication: Coronary heart disease risk by Framingham risk score in hepatitis C and HIV\/hepatitis C-coinfected persons. AIDS Res Hum Retrovir. 2015;31:718\u201322. Assessment of cardiovascular risk by Framingham risk score among HCV and HIV\/HCV-co-infected patients.","DOI":"10.1089\/aid.2014.0284"},{"key":"333_CR126","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-1293.2012.00996.x","volume":"13","author":"FM Islam","year":"2012","unstructured":"Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453\u201368.","journal-title":"HIV Med"},{"key":"333_CR127","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"ISS Group","year":"2015","unstructured":"Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807.","journal-title":"N Engl J Med"},{"key":"333_CR128","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","volume":"197","author":"S Emery","year":"2008","unstructured":"Strategies for Management of Antiretroviral Therapy Study G, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133\u201344.","journal-title":"J Infect Dis"},{"key":"333_CR129","unstructured":"El-Sadr WM, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver; 2006."},{"key":"333_CR130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/QAI.0000000000000662","volume":"69","author":"J Young","year":"2015","unstructured":"Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69:413\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR131","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","volume":"33","author":"JS Currier","year":"2003","unstructured":"Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506\u201312.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR132","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e328349c67a","volume":"25","author":"C Chao","year":"2011","unstructured":"Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011;25:1771\u20137.","journal-title":"AIDS"},{"key":"333_CR133","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/cid\/cit053","volume":"56","author":"ET Overton","year":"2013","unstructured":"Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471\u20139.","journal-title":"Clin Infect Dis"},{"key":"333_CR134","volume":"6","author":"RD Moore","year":"2011","unstructured":"Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6, e21843.","journal-title":"PLoS One"},{"key":"333_CR135","doi-asserted-by":"crossref","unstructured":"Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156\u201364. This study shows that statins decrease vascular inflammation in HIV-infected subjects and might therefore be associated with decreased risk of cardiovascular events.","DOI":"10.1093\/infdis\/jiu012"},{"key":"333_CR136","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/QAI.0000000000000478","volume":"68","author":"NT Funderburg","year":"2015","unstructured":"Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68:396\u2013404.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"333_CR137","first-page":"146","volume":"23","author":"JM Gilbert","year":"2015","unstructured":"Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2015;23:146\u20139.","journal-title":"Top Antivir Med"},{"key":"333_CR138","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","volume":"64","author":"YC Hsu","year":"2015","unstructured":"Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495\u2013503.","journal-title":"Gut"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-016-0333-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-016-0333-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-016-0333-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:45:29Z","timestamp":1749573929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-016-0333-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":138,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s11904-016-0333-9","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]}}}